AstraZeneca’s Symbicort inhaler accounts for most of ... choosing the best therapy for each patient. "Are dry powder inhalers the key to sustainable respiratory care?" was originally created ...

Symbicort is a type of inhaled long-term asthma medication. It combines two active ingredients in one inhaler: a corticosteroid called budesonide and a bronchodilator called formoterol.

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...